司來吉蘭與普拉克索分別輔助多巴絲肼片治療中晚期帕金森病的效果對(duì)比

賴穗翩 陳鉅濤 黎冠東

[摘要]目的 比較司來吉蘭與普拉克索分別輔助多巴絲肼片改善中晚期帕金森病的效果。方法 分析我院2014年7月～2017年6月收治的50例帕金森病患者臨床資料，依據(jù)用藥方案不同分為對(duì)照組（司來吉蘭聯(lián)合多巴絲肼片，25例）和觀察組（普拉克索聯(lián)合多巴絲肼片，25例），觀察兩組治療前后帕金森病綜合評(píng)分量表（UPDRS）評(píng)分和漢密爾頓抑郁量表（HAMD）評(píng)分情況，觀察兩組臨床效果和不良反應(yīng)發(fā)生率情況。結(jié)果 兩組治療前UPDRS和HAMD評(píng)分比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05），兩組治療后UPDRS和HAMD評(píng)分均低于治療前，觀察組治療后UPDRS和HAMD評(píng)分均低于對(duì)照組（P<0.05），觀察組的臨床治療總有效率高于對(duì)照組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組的不良反應(yīng)總發(fā)生率比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論 對(duì)中晚期帕金森病患者的治療，普拉克索聯(lián)合多巴絲肼片比司來吉蘭的UPDRS和HAMD評(píng)分改善更明顯，效果更良好。

[關(guān)鍵詞]司來吉蘭;普拉克索;多巴絲肼片;中晚期帕金森病

[中圖分類號(hào)] R742.5? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-4721（2019）2（a）-0080-03

[Abstract] Objective To compare the effect of Selegiline and Pramipexole respectively assisting on Levodopa and Benserazide Tablets in the treatment of middle and advanced Parkinson′s disease. Methods The clinical data of 50 patients with Parkinson′s disease admitted to our hospital from July 2014 to June 2017 were analyzed. According to different medication regimens， they were equally divided into control group （Selegiline combined with Levodopa and Benserazide Tablets） and observation group （Pramipexole combined with Levodopa and Benserazide Tablets）， 25 cases in each group. The unified parkinson′s disease rating scale （UPDRS） score and the Hamilton depression scale （HAMD） score before and after treatment were observed. The clinical effect and incidence of adverse reactions of the two groups were observed. Results The differences of UPDRS score and HAMD score between the two groups before treatment was not statistically significant （P>0.05）. After treatment， the UPDRS score and HAMD score of the two groups were both lower than those before treatment （P<0.05）. The UPDRS score and HAMD score of the observation group after treatment were both lower comarped with those in the control group （P<0.05）. The total clinical effectiveness rate was higher in the observation group than that in the control group with statistical significance （P<0.05）. There was no significant difference in the total incidence of adverse reactions between the two groups （P>0.05）. Conclusion For patients with middle and advanced Parkinson′s disease， the UPDRS score and the HAMD score are markedly improved with a better effect in Pramipexole combined with Levodopa and Benserazide Tablets compared with Selegiline combined with Levodopa and Benserazide Tablets.

[Key words] Selegiline; Pramipexole; Levodopa and Benserazide Tablets; Middle and advanced Parkinson′s disease